EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis
Author(s) -
Andrew L. Snow,
Stacie Lambert,
Yasodha Natkunam,
Carlos O. Esquivel,
Sheri M. Krams,
Olivia M. Martinez
Publication year - 2006
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.177.5.3283
Subject(s) - apoptosis , biology , programmed cell death , microbiology and biotechnology , receptor , fas receptor , b cell , cancer research , virology , immunology , antibody , genetics
The relationship between EBV infection and sensitivity to death receptor (DR)-induced apoptosis is poorly understood. Using EBV- and EBV+ BJAB cells, we provide the first evidence that EBV can protect latently infected B cell lymphomas from apoptosis triggered through Fas or TRAIL receptors. Caspase 8 activation was impaired and cellular FLIP recruitment was enriched in death-inducing signaling complexes formed in EBV-infected BJAB cells relative to parent BJAB cells. Furthermore, latent membrane protein 1 expression alone could reduce caspase activation and confer partial resistance to DR apoptosis in BJAB cells. This protective effect was dependent on C-terminal activating region 2-driven NF-kappaB activation, which in turn up-regulated cellular FLIP expression in latent membrane protein 1+ BJAB cells. Thus, the ability of latent EBV to block DR apoptosis may help to ensure the survival of host cells during B cell differentiation, and contribute to the development of B cell lymphomas, especially in immunocompromised individuals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom